Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Aliskiren (Drug); Valsartan (Drug); Placebo for Aliskiren (Drug); Placebo for Valsartan (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Novartis Official(s) and/or principal investigator(s): Novartis, Study Director, Affiliation: Novartis
Summary
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the
combination of aliskiren and valsartan, as initial therapy, compared to valsartan
monotherapy in Type II Diabetic patients with Stage II hypertension.
Clinical Details
Official title: An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8
Secondary outcome: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP) at Week 8 Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (MAPP) at Week 8 Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) Change From Baseline in Mean Sitting Pulse Pressure (MSPP) at Week 8 Percentage of Patients Achieving Blood Pressure Control Percentage of Responders Change From Baseline in Plasma Renin Activity (PRA) at Week 8 Change From Baseline in Plasma Renin Concentration (PRC) at Week 8 Change From Baseline in Plasma Aldosterone at Week 8 Number of Patients With Adverse Events, Serious Adverse Events and Death
Detailed description:
When protocol Amendment 2 was released, there were patients who had already been randomized
into the study. These patients were included in the trial prior to making changes to the
eligibility criteria. Thus, the study contains 2 distinct cohorts. Cohort 1 contains those
patients who had already been randomized, and had been deemed eligible based on the original
inclusion/exclusion criteria, prior to Amendment 2. No new patients were randomized to
Cohort 1. Cohort 2 contains patients who were randomized, having been found eligible based
on the revised inclusion/exclusion criteria, after Amendment 2. Differences in the inclusion
and exclusion criteria are indicated below.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients who are eligible and able to participate in the study, and who give written
informed consent before any assessment is performed.
- Men or women 18 years and older.
- Patients with Type 2 diabetes mellitus with an HbA1c ≤ 9 % at visit 1 and on a stable
anti-diabetic regimen not including insulin or stable diet and exercise for at least
4 weeks prior to visit 1.
Cohort 1:
- Patients with Stage 2 systolic hypertension, defined as having a MSSBP ≥160 mmHg and
<200 mmHg at Visit 5 (randomization).
- Patients who have been newly diagnosed with hypertension or who have not received
antihypertensive medication for at least 4 weeks (28 days) prior to Visit 1 must have
MSSBP ≥ 160 mmHg and < 200 mmHg at Visit 1, otherwise, they will be considered screen
failures.
- Patients receiving antihypertensive medication must have a MSSBP of ≥150 mmHg and
<200 mmHg at Study Visit 1, otherwise they will be considered screen failures.
Cohort 2:
- Patients must also have had a mean 8-hour daytime ambulatory systolic blood pressure
(ASBP) ≥140 mmHg AND mean 8-hour daytime ambulatory diastolic blood pressure (ADBP)
≥90 mmHg at Visit 5 (randomization).
- Hypertensive patients with MSSBP ≥150 mmHg and but <200 mmHg AND MSDBP ≥95 but <120
mmHg at Visit 5 (randomization).
- Patients who had been newly diagnosed with hypertension or who had not received
antihypertensive medication for at least 4 weeks (28 days) prior to Visit 1 must have
had MSSBP ≥150 mmHg but <200 mmHg and MSDBP ≥95 but <120 mmHg at Visit 1, otherwise,
they were considered screen failures.
Exclusion Criteria:
- Office blood pressure measured by cuff (MSSBP ≥200 mmHg or MSDBP ≥120 mmHg).
- History or evidence of secondary hypertension of any etiology.
- Refractory hypertension, defined as having uncontrolled BP (≥140/90 mmHg) while
receiving 3 antihypertensive medications at the maximum approved dose of each drug,
one of which must be a diuretic.
- Patients treated with more than 3 antihypertensive medications (each component of a
combination drug counts individually).
- Type 2 diabetes mellitus currently requiring insulin treatment.
- modification of diet in renal disease (MDRD) estimated glomerular filtration rate
(eGFR) < 60 mL/min/1. 73m2
- Serum sodium less than lower limit of normal, serum potassium < 3. 5 mEq/L or ≥ 5. 3
mEq/L at Visit 1.
- Known Keith-Wagener grade III or IV hypertensive retinopathy.
Cohort 1:
- Patients with known diabetic retinopathy (eg, having a history of laser therapy for
diabetic retinopathy) or diabetic neuropathy (eg, receiving medication for diabetic
neuropathy).
Cohort 2:
- Patients with known diabetic retinopathy or diabetic neuropathy and/or having a history
of treatment for either.
Other protocol-defined inclusion/exclusion criteria applied.
Locations and Contacts
Investigative Site, Newark, Delaware USA, United States
Investigative Site, Kansas, Missouri, United States
Investigative Site, Camden, New Jersey, United States
Investigative Site, Philadelphia, Pennsylvania, United States
Additional Information
Starting date: May 2009
Last updated: December 3, 2012
|